Pfizer Inc. (NYSE:PFE) stock lost over 0.7% on September 13th, 2017 (as of 12:54PM EDT; Source: Google finance) but rallied over 3.3% in the last five days.
Oxbow Advisors LLC has boosted its position in shares of PFE by 1.0% in the 2nd quarter, as per the company in its most recent 13F filing with the Securities and Exchange Commission. A number of other large investors have also recently bought and sold shares of PFE. Chevy Chase Trust Holdings Inc. boosted its holdings in shares of Pfizer by 0.9% during the 1st quarter. Chevy Chase Trust Holdings Inc. now owns 5,428,710 shares of the biopharmaceutical company’s stock worth $185,715,000 after purchasing an additional 46,366 shares during the last quarter.
Meanwhile, Pfizer lung cancer drug’s overall survival data is unfavorable. PFE has announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). Xalkori is currently approved for the treatment of ALK+ or ROS1-positive locally advanced or metastatic NSCLC. The product had generated sales of $296 million in the first half of 2017, up 8% year over year. In the PROFILE 1014 study, a statistically significant improvement in overall survival (OS) rates was not observed in patients treated with Xalkori. After a median follow-up of 46 months, the median OS for patients treated with Xalkori was 45.8 months while it was 47.5 months for patients randomized to chemotherapy. PROFILE 1014 has provided important new data for patients with non-small cell lung cancer.
Moreover, PFE is is aggressively working on expanding the labels of its marketed cancer drugs like Ibrance and Xalkori. Pfizer’s newly approved immunotherapy, Bavencio, is expected to contribute significantly to the top line. Bavencio is under review in the EU for MCC with a decision expected in the third quarter of 2017. Pfizer along with partner Merck KGaA is focusing on continuously growing and expanding Bavencio into new indications and markets globally.
Additionally, PFE’s two other oncology candidates have also been approved by the FDA recently. These include Besponsa for relapsed/refractory acute lymphoblastic leukemia in August and Mylotarg for new or relapsed CD33-positive acute myeloid leukemia in September. Other cancer candidates in PFE’s pipeline include talazoparib (advanced breast cancer) and dacomitinib (advanced NSCLC with EGFR activating mutations).
PFE stock has risen 3.72% in a year (source: Google Finance).